PT-141 (Bremelanotide)

Common side effects:

• Nausea, which is the most frequently reported adverse event
• Flushing or redness of the skin
• Injection site reactions including pain, redness, or itching
• Headache and dizziness
• Transient increases in blood pressure and decreases in heart rate

Rare or serious side effects:

• Focal hyperpigmentation, particularly on the face or gums
• Severe nausea requiring antiemetic medication
• Significant, sustained hypertension
• Allergic reactions or hypersensitivity

Central melanocortin activation is the primary mechanism by which the PT-141 (Bremelanotide) peptide exerts its effects. It functions as a non-selective agonist of the melanocortin receptors, with a particularly high affinity for the melanocortin 4 receptor (MC4R) located in the central nervous system. By binding to MC4R in the hypothalamus, the peptide stimulates neural pathways that regulate sexual desire and arousal, bypassing the peripheral vascular system entirely (Sweeney et al., 2023).

Dopaminergic pathway modulation occurs as a downstream effect of this MC4R activation. The stimulation of these central receptors triggers the release of dopamine in the medial preoptic area of the brain, a region critical for sexual behavior. This neurochemical cascade translates into the physiological and psychological arousal characteristic of PT-141, distinguishing it from traditional PDE5 inhibitors that solely rely on nitric oxide-mediated vasodilation (Pettigrew & Novick, 2021).

Discovery and early development of PT-141 stemmed from research into Melanotan II, a synthetic peptide originally investigated for its skin-tanning properties. Researchers noted that Melanotan II induced spontaneous sexual arousal as a side effect, prompting the isolation of bremelanotide as a metabolite that retained the sexual health benefits without the potent melanogenic effects. Palatin Technologies subsequently developed PT-141 specifically to target sexual dysfunction in both men and women (Hedlund, 2004).

Regulatory milestones culminated in 2019 when the FDA officially approved bremelanotide under the brand name Vyleesi. The approval was based on successful Phase 3 clinical trials demonstrating its efficacy and safety for premenopausal women with acquired, generalized hypoactive sexual desire disorder (NCT02333071). Today, it is prescribed as an on-demand subcutaneous injection, representing a significant advancement in the medical treatment of female sexual dysfunction (Mayer & Lynch, 2020).